Bilici, A. Et Al. 2022. Real-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study). . ASCO 2022 , (Illinois, United States Of America), 105.

Bilici, A., Ölmez, Ö. F., Sezer, A., Öksüzoğlu, B., Kaplan, M., Karadurmuş, N., ... Çubukçu, E.(2022). Real-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study). . ASCO 2022 (pp.105). Illinois, United States Of America

Bilici, Ahmet Et Al. "Real-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study). ," ASCO 2022, Illinois, United States Of America, 2022

Bilici, Ahmet Et Al. "Real-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study). ." ASCO 2022 , Illinois, United States Of America, pp.105, 2022

Bilici, A. Et Al. (2022) . "Real-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study). ." ASCO 2022 , Illinois, United States Of America, p.105.

@conferencepaper{conferencepaper, author={Ahmet Bilici Et Al. }, title={Real-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study). }, congress name={ASCO 2022}, city={Illinois}, country={United States Of America}, year={2022}, pages={105} }